DiaMedica Therapeutics Announces Promising Interim Phase 2 Results for Preeclampsia Treatment with DM199, Showing Significant Blood Pressure Reduction and No Placental Transfer
Reuters
Jul 17
DiaMedica <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Interim Phase 2 Results for Preeclampsia Treatment with DM199, Showing Significant Blood Pressure Reduction and No Placental Transfer
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced positive interim results from Part 1a of its Phase 2 study of DM199 for the treatment of preeclampsia. The study, which is open-label and investigator-sponsored, demonstrated statistically significant reductions in both systolic and diastolic blood pressure, as well as a significant reduction in the uterine artery pulsatility index. Importantly, DM199 did not cross the placental barrier and was generally safe and well-tolerated. The study achieved pre-specified safety and efficacy endpoints, reinforcing DM199's therapeutic potential as a first-in-class, disease modifying therapy for preeclampsia. Currently, there are no approved pharmacological treatments for preeclampsia in the United States and Europe. DiaMedica Therapeutics plans to discuss these interim results further during a conference call and webcast scheduled for July 17, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250717976890) on July 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.